| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Ipriflavone targets bone cells, specifically osteoblasts and osteoclasts. It is known to inhibit bone resorption and stimulate osteoblast activity. It has been shown to reduce calcium release from bone cultures and inhibit osteoclast activity. It directly stimulates markers of the osteoblast phenotype at a certain stage in bone formation.
|
|---|---|
| ln Vitro |
Ipriflavone decreases the proliferation and DNA synthesis of MDA-231 cells and suppresses ligand-induced EGFR Tyr(845) phosphorylation. Yipflavone does not increase apoptosis of MDA-231 cells [1]. Isopreflavone can also stimulate calcium deposition and the production of mineralized nodules in newborn rat skull osteoblast-like cells as well as alkaline phosphatase activity [2].
Ipriflavone promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like (ROB) cells. It stimulates the activity of alkaline phosphatase, a marker of osteoblast differentiation. It protects against cyclophosphamide-induced DNA damage. Its in vitro activity has been confirmed in various bone cell assays. |
| ln Vivo |
Daily oral administration of ipriflavone 12 mg/mouse can greatly suppress the emergence of new osteolytic bone metastases and the progression of established osteolytic lesions, consequently increasing the longevity of tumor-bearing mice. Isoflavone lowers the number of osteoclasts at the bone-cancer interface without substantial negative effects on the host [1]. One month of isoflavone therapy increases bone density and improves biomechanical qualities of adult rat male bones without affecting mineral composition[3]
In animal models of low Ca2+ diet, Ipriflavone decreases bone resorption and increases bone density and volume. It has been used to prevent osteoporosis in postmenopausal women and to maintain bone density. Its ability to inhibit bone resorption and stimulate bone formation contributes to its effects on bone mass. |
| Enzyme Assay |
The primary in vitro assays for Ipriflavone include osteoblast differentiation assays, where its ability to stimulate alkaline phosphatase activity and mineralization is measured in osteoblast-like cells. Osteoclast activity assays measure its ability to inhibit bone resorption in osteoclast cultures.
|
| Cell Assay |
Cellular assays for Ipriflavone involve treating osteoblast-like cells or osteoclasts with the compound and measuring its effects on cell differentiation, activity, and survival. Its ability to stimulate osteoblast markers, such as alkaline phosphatase and osteocalcin, is assessed. Its ability to inhibit osteoclast-mediated bone resorption is measured in bone resorption assays.
|
| Animal Protocol |
In vivo animal experiments for Ipriflavone have been conducted in animal models of low Ca2+ diet, where it decreases bone resorption and increases bone density and volume. Its effects on bone mass and bone turnover markers have been evaluated. Clinical studies have been conducted in postmenopausal women to assess its efficacy in preventing osteoporosis.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known human metabolites of isoflavones include 3-phenyl-7-(1-methyl-2-hydroxyethoxy)-4H-1-benzopyran-4-one, 7-hydroxyisoflavone and 4H-1-benzopyran-4-one, 3-(4-hydroxyphenyl)-7-(1-methylethoxy)-. Ipriflavone has a molecular weight of 294.35 g/mol and a molecular formula of C18H18O3. It is a synthetic isoflavone derivative. It is typically used as a research reagent. Its purity is typically ≥99%. The compound is also known as 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one. |
| Toxicity/Toxicokinetics |
The toxicological profile of Ipriflavone is characteristic of isoflavone derivatives. Common adverse effects may include gastrointestinal disturbances. Its safety has been evaluated in clinical studies for the prevention of osteoporosis. It is generally well-tolerated.
|
| References |
|
| Additional Infomation |
Ipriflavone belong to the isoflavone class of compounds, characterized by the substitution of the 7th hydrogen atom with an isopropoxy group. As a synthetic isoflavone, it was once used to treat osteoporosis, but a randomized controlled trial failed to confirm its efficacy. Currently, it is still used to prevent osteoporosis in postmenopausal women and to maintain bone density. It belongs to the isoflavone class and is also an aromatic ether.
Ipriflavone is a synthetic isoflavone derivative used to inhibit bone resorption and maintain bone density. It stimulates osteoblast activity and inhibits osteoclast activity. It has been used to prevent osteoporosis in postmenopausal women. It is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C18H16O3
|
|---|---|
| Molecular Weight |
280.323
|
| Exact Mass |
280.109
|
| CAS # |
35212-22-7
|
| PubChem CID |
3747
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
435.9±45.0 °C at 760 mmHg
|
| Melting Point |
116-120 °C(lit.)
|
| Flash Point |
209.3±15.1 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
4.37
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
407
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(C2=CC=CC=C2)=COC3=CC(OC(C)C)=CC=C13
|
| InChi Key |
SFBODOKJTYAUCM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
|
| Chemical Name |
3-phenyl-7-propan-2-yloxychromen-4-one
|
| Synonyms |
FL 113; FL-113; Ipriflavone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~118.90 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL | |
| 5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL | |
| 10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
